Joseph  Romanelli net worth and biography

Joseph Romanelli Biography and Net Worth

Insider of Merck & Co., Inc.
Joseph Romanelli is president, Human Health International for Merck. He has P&L responsibility for Merck’s 75-plus markets outside of the U.S. and leads a team of 14,000 colleagues.  

From 2021 to mid-2022, Joseph served as chief executive officer of JiXing Pharmaceuticals, a China-based biopharmaceutical company.

Prior to JiXing, Joseph served in a variety of strategic and operational roles with increasing responsibility at Merck and Schering-Plough for 25 years. He led Merck’s business in China from 2016 through 2021. During his tenure in China, Merck became the second largest multi-national pharmaceutical company by revenue in the market, as well as the second largest subsidiary for the company globally. Joseph’s previous roles at Merck include serving as chief of staff to the president of Human Health and managing the Human Health business for multiple markets in Asia Pacific. In addition, he led the Investor Relations team at Merck.

Joseph received his undergraduate degree from the University of Delaware and his master’s in Business Administration from Fordham University’s Gabelli School of Management.

What is Joseph Romanelli's net worth?

The estimated net worth of Joseph Romanelli is at least $2.48 million as of February 13th, 2024. Mr. Romanelli owns 19,569 shares of Merck & Co., Inc. stock worth more than $2,484,089 as of April 23rd. This net worth evaluation does not reflect any other investments that Mr. Romanelli may own. Learn More about Joseph Romanelli's net worth.

How do I contact Joseph Romanelli?

The corporate mailing address for Mr. Romanelli and other Merck & Co., Inc. executives is 2000 GALLOPING HILL ROAD, KENILWORTH NJ, 07033. Merck & Co., Inc. can also be reached via phone at (908) 740-4000 and via email at [email protected]. Learn More on Joseph Romanelli's contact information.

Has Joseph Romanelli been buying or selling shares of Merck & Co., Inc.?

Joseph Romanelli has not been actively trading shares of Merck & Co., Inc. over the course of the past ninety days. Most recently, Joseph Romanelli sold 1,000 shares of the business's stock in a transaction on Tuesday, February 13th. The shares were sold at an average price of $124.89, for a transaction totalling $124,890.00. Following the completion of the sale, the insider now directly owns 19,569 shares of the company's stock, valued at $2,443,972.41. Learn More on Joseph Romanelli's trading history.

Who are Merck & Co., Inc.'s active insiders?

Merck & Co., Inc.'s insider roster includes Sanat Chattopadhyay (Insider), Frank Clyburn (EVP), Robert Davis (CFO), Richard Deluca (EVP), Kenneth Frazier (Insider), Julie Gerberding (EVP), Clark Golestani (EVP), Michael Holston (EVP), Rita Karachun (VP), Caroline Litchfield (CFO), Steven Mizell (EVP), Johannes Oosthuizen (Insider), Joseph Romanelli (Insider), Ashley Watson (SVP), and Wendell Weeks (Director). Learn More on Merck & Co., Inc.'s active insiders.

Are insiders buying or selling shares of Merck & Co., Inc.?

During the last year, Merck & Co., Inc. insiders bought shares 1 times. They purchased a total of 3 shares worth more than $341.04. During the last year, insiders at the sold shares 11 times. They sold a total of 460,551 shares worth more than $53,354,373.87. The most recent insider tranaction occured on February, 13th when insider Joseph Romanelli sold 1,000 shares worth more than $124,890.00. Insiders at Merck & Co., Inc. own 0.1% of the company. Learn More about insider trades at Merck & Co., Inc..

Information on this page was last updated on 2/13/2024.

Joseph Romanelli Insider Trading History at Merck & Co., Inc.

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/13/2024Sell1,000$124.89$124,890.0019,569View SEC Filing Icon  
4/26/2023Buy3$113.68$341.0420,599View SEC Filing Icon  
3/24/2023Sell35$104.65$3,662.7520,596View SEC Filing Icon  
3/20/2023Buy136$105.47$14,343.9220,631View SEC Filing Icon  
2/21/2023Buy11$109.20$1,201.2020,495View SEC Filing Icon  
2/15/2023Sell5,000$108.22$541,100.0020,284View SEC Filing Icon  
See Full Table

Joseph Romanelli Buying and Selling Activity at Merck & Co., Inc.

This chart shows Joseph Romanelli's buying and selling at Merck & Co., Inc. by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Merck & Co., Inc. Company Overview

Merck & Co., Inc. logo
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. The company serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians, wholesalers, government entities, veterinarians, distributors, animal producers, farmers, and pet owners. It has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates, which include patritumab deruxtecan, ifinatamab deruxtecan, and raludotatug deruxtecan for the treatment of multiple solid tumors both as monotherapy and/or in combination with other treatments; and AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types, and Koselugo for multiple indications. The company also has a collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. was founded in 1891 and is headquartered in Rahway, New Jersey.
Read More

Today's Range

Now: $127.12
Low: $126.83
High: $128.10

50 Day Range

MA: $126.21
Low: $120.54
High: $131.95

2 Week Range

Now: $127.12
Low: $99.14
High: $133.10

Volume

2,739,869 shs

Average Volume

8,236,807 shs

Market Capitalization

$322.00 billion

P/E Ratio

908.00

Dividend Yield

2.45%

Beta

0.38